Hyperoside alleviates postmenopausal osteoporosis via regulating miR-19a-5p/IL-17A axis.
American journal of reproductive immunology (New York, N.Y. : 1989)(2023)
Abstract
Overall, these data demonstrated that miR-19a-5p/IL-17A axis might serve as novel therapeutic candidate for PMO. Hyp could relieve bone resorption by targeting the miR-19a-5p/IL-17A axis in OVX mice and exhibited prospective for the treatment of PMO.
MoreTranslated text
Key words
Hyperoside, IL-17A, miRNA-19a-5p, postmenopausal osteoporosis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined